NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center will have a high profile at the 51st Annual Meeting of the American Society for Clinical Oncology (ASCO), with researchers presenting close to 30 abstracts accepted for oral, poster and publication presentations.
Conferences
FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma
CAMBRIDGE, Mass. Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has been granted Orphan Disease Designation by the FDA for its drug AU-011 for the treatment of Uveal Melanoma. The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics, which demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions in the US. In addition, the first oral presentation of Aura Biosciences’ pre-clinical research, ‘Evaluating the in vivo efficacy of a first-in-class drug for the treatment of primary uveal melanoma’, was recently delivered by McGill University Health Centre researchers at the ARVO (Association for Research in Vision and Ophthalmology) Annual Meeting.
Robert H. Pierce, MD, Chief Scientific Officer of OncoSec Medical, Invited to Present at 11th Annual PEGS Conference in Boston
Preliminary Results Suggest ImmunoPulse™ IL-12 May Generate Increased TILs and CD8+ T-Cell Infiltration in Merkel Cell Carcinoma and Melanoma Patients
Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma
Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, will present new research on its 105F immunomodulatory treatment candidate for melanoma during the 2015 Society of Investigative Dermatology (SID) Annual Meeting, taking place May 6-9, 2015 in Atlanta, GA.